Project Description

Dr. Steven T. Forman, MD, FACC, FSCAI, RVT

Dr. Steven Forman joined Los Alamitos Cardiovascular in 1999 and has been its managing partner since 2005. In addition to his roles at Los Alamitos Cardiovascular, Dr. Forman is director of Performance Vein Institute of Los Alamitos—a practice focused on the diagnosis and treatment of vein disease of the lower extremities. Dr. Forman is board certified in Interventional Cardiology, Cardiovascular Disease and Venous and Lymphatic Medicine. In December 2015, he completed a two-year term as chief of staff at Los Alamitos Medical Center (LAMC), and since 2014, Dr. Forman has been the director of LAMC’s Cardiac Catheterization Lab. In 2018, Dr. Forman became chairperson of LAMC’s Board of Governors.

Dr. Steven T. Forman at Work

Dr. Steven T. Forman’s Curriculum Vitae

Click here to download as a PDF


Cardiology, Interventional Cardiology, Endovascular Diseases, Venous and Lymphatic Medicine

Board Certifications:

  • Certified in Venous and Lymphatic Medicine
    American Board of Venous and Lymphatic Medicine (ABVLM) 2012
  • Certified in Interventional Cardiology
    American Board of Internal Medicine
    1999 (Recertification 2009)
  • Certified in Cardiovascular Disease
    American Board of Internal Medicine
    1997 (Recertification 2017)
  • Expert Reviewer
    The Medical Board of California
    August 2014-Present

Additional Certifications:

  • GCP Certified July 2010
    CITI Collaborative Institutional Training Initiative

Current Hospital Appointments:

  • Los Alamitos Medical Center
    3751 Katella Avenue
    Los Alamitos, California 90720
  • MemorialCare Health System
    Long Beach Memorial Medical Center
    2801 Atlantic Avenue
    Long Beach, California 90801
  • Lakewood Regional Medical Center
    3700 South Street
    Lakewood, California 90712


Los Alamitos Medical Center

  • Chairman, Board of Governors
    January 2018 – December 2019
  • Director of Cardiac Catheterization Lab
    Effective March 2014
  • Chief of Staff
    January 2013 – December 2014
  • Chairman of Elective PCI Pilot Program
    June 2010 – 2014
  • Vice Chief of Staff, Medical Executive Committee
    January 2012 – December 2013
  • Secretary/Treasurer, Medical Executive Committee
    January 2010 – December 2011
  • Chief of Medicine
    January 2007 – December 2010
  • Chairman of Allied Health Committee
    January 2006 – December 2006
  • Member, Medical Executive Committee
    January 2006 – Present
  • Member, Myocardial Infarction Quality Assurance Committee
    January 2001 – Present
  • Member, Cardiovascular Quality Assurance Committee
    January 2000 – Present

State of California

  • Member, AOC (Advisory Oversight Committee) for the Elective PCI (Percutaneous Coronary Interventions) Pilot Program for the State of California
    June 2010 – 2014

Professional Societies:

  • American College of Phlebology (RVT)
  • American College of Cardiology (FACC)
  • American College of Physicians (FACP)
  • Society for Cardiovascular Angiography and Intervention

Academic Appointments:

  • Volunteer Faculty
    Department of Medicine/Division of Cardiology
    University of California , Irvine (UCI)
    November 2011 – Present
  • Instructor in Medicine
    Department of Medicine
    The New York Hospital /Cornell University Medical Center
    June 1996 – June 1998

Work History:

  • Los Alamitos Cardiovascular
    Los Alamitos, California
    1999 – Present
  • Cardiology Associates of North Jersey
    1030 Clifton Avenue
    Clifton, New Jersey 07013
    July 1998 – August 1999
  • Urgent Care Physician
    Memorial Sloan Kettering Cancer Center
    New York, New York
    July 1994 – June 1996

Previous Hospital Appointments:

  • General Hospital of Passaic
    350 Boulevard
    Passaic, New Jersey 07055
    July 1998 – August 1999
  • Saint Mary’s Hospital
    211 Pennington Avenue
    Passaic, New Jersey 07055
    July 1998 – August 1999
  • Saint Joseph’s Hospital and Medical Center
    703 Main Street
    Passaic, New Jersey 07055
    July 1998 – August 1999
  • Chilton Memorial Hospital
    97 West Parkway
    Pomptom Plains, New Jersey 07444
    July 1998 – August 1999
  • Passaic Beth Israel Hospital
    70 Parker Avenue
    Passaic, New Jersey 07055
    July 1998 – August 1999


  • Shaknovich A, Forman ST, Parikh M, Deutsch E, Bergman G, McCaffery T, Newman GC, Tarazona N and Sanborn T. “Novel distal occluder washout methods for prevention of no-reflow during stenting of saphenous vein grafts.” Catheter Cardiovascular Intervention. 1999 Aug: 47(4): 397 – 403.
  • Marshall ES, Raichlen JS, Forman S, Heyrich GP, Keen WD, Weitz HH. “Adenosine radionuclide perfusion imaging in the preoperative evaluation of patients undergoing peripheral vascular surgery.” American Journal of Cardiology. 1995 Oct 15: 76(11): 817 – 821.


  • Interventional Cardiology Fellowship
    The New York Hospital – Cornell University Medical Center
    The Division of Cardiology
    New York, New York
    July 1997 – June 1998
  • Cardiovascular Diseases Fellowship
    The New York Hospital – Cornell University Medical Center
    New York, New York
    July 1994 – June 1997
  • Internal Medicine Internship and Residency
    Thomas Jefferson University Hospital
    Department of Medicine
    Philadelphia, Pennsylvania
    July 1991 – June 1994
  • Medical Education
    Albany Medical College
    Albany, New York
    MD, May 1991
  • Undergraduate Education
    The Johns Hopkins University
    Baltimore, Maryland
    Bachelor of Arts in Natural Science, May 1987

Research Experience:

  • AEGIS: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome.
    Sub-Investigator | 2019
    Sponsor: CSL Behring LLC
  • COVET : Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots).
    Principal Investigator | 2018 – Present
    Sponsor : Patient-Centered Outcomes Research Institute (PCORI)
  • NODE 301: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia.
    Sub-Investigator | 2019
    Sponsor: Milestone Pharmaceuticals Inc.
  • NODE 302: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301).
    Sub-Investigator | 2019
    Sponsor: Milestone Pharmaceuticals Inc.
  • PARADISE MI: A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
    Sub-Investigator | 2018 – Present
    Sponsor: Novartis
  • PEA-VALVE: Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms.
    Principal Investigator | 2018 – Present
    Sponsor: Eko Devices
  • GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
    Principal Investigator | 2017 – Present
    Sponsor: Amgen
    NCT02929329 |
  • PROVE-HF: A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
    Sub-Investigator | 2017 – 2019
    Sponsor: Novartis
    NCT02887183 |
  • Barostim Therapy for Heart Failure (BeAT-HF): The Barostim Neo – Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
    Principal Investigator | 2016 – Present
    Sponsor: CVRx, Inc.
    NCT02627196 |
  • MLHFQ Study: Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
    Principal Investigator | 2016 – 2017
    Sponsor: Gilead/ICON
  • THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS – Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
    Sub-Investigator | 2015 – Present
    Sponsor: AstraZeneca
    NCT01991795 | 
  • Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
    Sub-Investigator | 2015 – 2016
    Sponsor: Amgen, Evidera
  • DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
    Principal Investigator | 2013 – 2018
    Sponsor: AstraZeneca
    NCT01730534 |
  • ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
    Sub-Investigator | 2013 – 2017
    Sponsor: Sanofi
    NCT01663402 |
  • SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.
    Sub-Investigator | 2013 – 2017
    Sponsor: Yale University School of Medicine/NIH
    NCT01755052 |
  • RivaroxAFL3003: An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
    Principal Investigator | 2013 – 2014
    Sponsor:  Janssen Scientific Affairs/Johnson & Johnson
  • Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.
    Principal Investigator | 2013
    Sponsor: Tasly Pharmaceuticals
    NCT0169580 |
  • Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
    Principal Investigator | 2013 – 2018
    Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
    NCT01594333 |
  • User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2PT/INR Monitoring System (ADAPT) BSTE-0159.
    Principal Investigator | 2012
    Sponsor: Alere San Diego
  • Mission® PT Coagulation Monitoring System Clinical Study.
    Sub-Investigator | 2012
    Sponsor: ACON Laboratories, INC.
  • The “BRIDGE” Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
    Principal Investigator | 2012 – 2015
    Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)
    NCT00786474 |
  • GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
    Principal Investigator | 2012 – Present
    Sponsor: Boehringer Ingelheim
    NCT01468701 |
  • California State Elective Percutaneous Coronary Intervention Pilot Program
    Principal Investigator | 2010 – 2014
  • BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
    Sub-Investigator | 2010 – 2012
    Sponsor: St. Jude Medical Center
    NCT01062126 |
  • The PROMISE Trial: PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
    Principal Investigator | 2010 – 2014
    Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
    NCT01174550 |
  • ORBIT-AF I and II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
    Principal Investigator | 2010 – 2017
    Sponsor: Janssen Scientific Affairs, LLC
    Collaborator: Duke Clinical Research
    NCT01165710 |
    NCT01701817 |
  • RATE: Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
    Sub-Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
    NCT00837798 |
  • FREEDOM: A Frequent Optimization Study the Quick Opt ™ Method.
    Sub-Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
    NCT00418314 |
  • ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation – Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE – AF TIMI – 48).
    Principal Investigator | 2009 – 2015
    Sponsor: Daiichi Sankyo Pharma Development
    NCT00781391 |
  • Phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of Dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV Risk in patients hospitalized for an acute coronary syndrome (ACS) when treatment is initiated within 1 week after an ACS (Dal-ACUTE).
    Principal Investigator | 2008 – 2012
    Sponsor: F.Hoffmann-La Roche Ltd., Hoffmann-La Roche, Inc. , Roche Global Development.
    NCT01323153 |
  • Multi-center, randomized, controlled study to investigate the safety and tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Iron Dextran in treating iron deficiency anemia in subjects who are not dialysis dependent.
    Principal Investigator | 2007 – 2009
    Sponsor: Luitpold Pharmaceuticals, Inc.
    NCT00704028 |
  • Systolic and diastolic myocardial dysfunction during endotoxemia in pigs. Proctor: Roy D Goldfarb, Phd | 1989 – 1991
    Department of Physiology, Albany Medical College